Metosyn Fapg (Fluocinonide)

Fluocinide is a potent topical corticosteroid used to manage inflammatory skin disorders.

• Psoriasis: reduces plaque thickness, erythema and scaling.
• Atopic dermatitis: alleviates itching, redness and swelling.
• Contact dermatitis: diminishes allergic skin reactions and inflammation.
• Lichen planus: controls lesions and associated discomfort.

• Fluocinide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and reduces vascular permeability, resulting in marked anti‑inflammatory and immunosuppressive effects at the site of application.

Fluocinide may cause local and systemic adverse reactions.

Common Side Effects

• Burning or stinging sensation at the application site.
• Pruritus or mild itching.
• Dryness or flaking of the skin.
• Erythema or mild redness.
• Folliculitis or acne‑like eruptions.
• Telangiectasia (visible small blood vessels).

Serious or Rare Side Effects

• Skin atrophy or thinning.
• Secondary bacterial, fungal or viral infections.
• Systemic adrenal suppression with extensive use.
• Hypersensitivity reactions such as urticaria or angioedema.
• Delayed wound healing.
• Hyperglycaemia in susceptible individuals.

When using Fluocinide, follow safety measures to minimise risks.

• Application area: limit use to affected skin only and avoid healthy skin.
• Duration of therapy: restrict continuous use to the shortest period required.
• Sensitive sites: avoid face, intertriginous areas and mucous membranes unless directed.
• Occlusion: do not cover treated skin with airtight dressings unless prescribed.
• Pediatric use: exercise caution in children due to higher per‑kg absorption.
• Systemic absorption: monitor for signs of adrenal suppression with extensive application.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluocinide can interact with other agents that affect corticosteroid activity or skin integrity.

Major Interactions (Avoid)

• Systemic corticosteroids: additive systemic glucocorticoid effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure.
• Immunosuppressants (e.g., tacrolimus): heightened risk of infection.
• Live vaccines: possible reduced vaccine efficacy.
• Antifungal or antibacterial topical agents: may increase local irritation.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied to the same area: increased irritation risk.
• Herbal preparations with corticosteroid‑like activity: potential additive effects.
• Phototherapy: may enhance skin thinning.
• Diabetic medications: monitor blood glucose if extensive skin absorption occurs.